Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
Eric Van CutsemUniversity Hospital Gasthuisberg, Leuven, Belgium. [email protected]Fernando RiveraDepartment of Medical Oncology, Hospital Marqués de Valdecilla, Santander, SpainScott BerryDepartment of Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, CanadaAlbrecht KretzschmarHaematology, Oncology and Tumour Immunology Clinic, HELIOS-Klinikum Berlin, Robert Rossle Charita Campus, Berlin, GermanyM. MichaelDivision of Haematology and Oncology, Peter MacCallum Cancer Institute, Melbourne, AustraliaM. DiBartolomeoMedical Oncology Unit 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyM. MazierDepartment of Biostatistics, Parexel, Paris, FranceJ.-L. CanonDepartment of Oncology/Hematology, Centre Hospitalier Notre Dame Reine Fabiola, Charleroi, BelgiumVassilis GeorgouliasDepartment of Medical Oncology, University General Hospital, Heraklion, GreeceMarc PeetersDigestive Oncology Unit, University Hospital, Gent, BelgiumJohn BridgewaterDepartment of Oncology, University College London Hospital, LondonDavid CunninghamGastrointestinal and Lymphoma Units, Royal Marsden Hospital, Sutton, UK
2009en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0